CN118488967A - 半乳凝素-10抗体 - Google Patents

半乳凝素-10抗体 Download PDF

Info

Publication number
CN118488967A
CN118488967A CN202380015480.6A CN202380015480A CN118488967A CN 118488967 A CN118488967 A CN 118488967A CN 202380015480 A CN202380015480 A CN 202380015480A CN 118488967 A CN118488967 A CN 118488967A
Authority
CN
China
Prior art keywords
antibody
antigen
domain
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380015480.6A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·塞巴斯蒂安·范德沃宁
让-米歇尔·佩尔西耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agence Co ltd
Original Assignee
Agence Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence Co ltd filed Critical Agence Co ltd
Publication of CN118488967A publication Critical patent/CN118488967A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380015480.6A 2022-01-18 2023-01-18 半乳凝素-10抗体 Pending CN118488967A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202200597 2022-01-18
GB2200597.9 2022-01-18
PCT/EP2023/051100 WO2023139107A1 (en) 2022-01-18 2023-01-18 Galectin-10 antibodies

Publications (1)

Publication Number Publication Date
CN118488967A true CN118488967A (zh) 2024-08-13

Family

ID=85037098

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380015480.6A Pending CN118488967A (zh) 2022-01-18 2023-01-18 半乳凝素-10抗体

Country Status (10)

Country Link
US (1) US20250059285A1 (https=)
EP (1) EP4466070A1 (https=)
JP (1) JP2025503707A (https=)
KR (1) KR20240133711A (https=)
CN (1) CN118488967A (https=)
AU (1) AU2023208882A1 (https=)
CA (1) CA3236108A1 (https=)
IL (1) IL314367A (https=)
MX (1) MX2024006275A (https=)
WO (1) WO2023139107A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118206657B (zh) * 2023-12-29 2025-03-07 康旭生物科技(深圳)有限公司 一种半乳糖凝集素-3的抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
AU2023208882A1 (en) 2024-05-09
MX2024006275A (es) 2024-06-11
IL314367A (en) 2024-09-01
WO2023139107A1 (en) 2023-07-27
EP4466070A1 (en) 2024-11-27
US20250059285A1 (en) 2025-02-20
JP2025503707A (ja) 2025-02-04
CA3236108A1 (en) 2023-07-27
KR20240133711A (ko) 2024-09-04

Similar Documents

Publication Publication Date Title
JP5575923B2 (ja) 抗凝固薬の解毒剤
AU2011208719B2 (en) Anticoagulant antidotes
CN109863174B (zh) 对FcγRIIA具有特异性的结合分子及其使用
CN113501878A (zh) 针对人tslp的多种抗体及其用途
AU2019250689A1 (en) Galectin-10 antibodies
KR20240049265A (ko) 인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법
JP2023528535A (ja) セリン４１３においてリン酸化されたタウを標的化する高親和性抗体
KR20240150774A (ko) 인간화된 항-tdp-43 결합 분자 및 이의 용도
TW202509068A (zh) 結合ox40l之抗體及使用方法
TW202448940A (zh) 結合介白素4受體α之抗體及其使用方法
JP2014515740A (ja) 抗凝固薬の解毒剤
JP2024522237A (ja) ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
KR20250004705A (ko) 항-tdp-43 결합 분자
US20250059285A1 (en) Galectin-10 antibodies
KR20250153801A (ko) Il-36r 결합 단백질 및 이의 의학적 용도
US20230110188A1 (en) MuSK AGONIST ANTIBODY
CN119137152A (zh) 抗par2抗体
HK40110366A (zh) 半乳凝素-10抗体
JP7735545B2 (ja) Ｃｄｃプラットホーム抗体
TW202607021A (zh) 結合ｔｓｌｐ之抗體及使用方法
AU2024331270A1 (en) Anti-tslp antibody constructs and uses thereof
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
WO2025241702A1 (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
TW202540170A (zh) 抗原結合蛋白
KR20240022546A (ko) 항il-36r 항체 및 그의 사용

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110366

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Sebastian Vandervonen

Inventor after: Jean Michel Percier

Inventor before: Paul Sebastian Vandervoning

Inventor before: Jean Michel Percier

CB03 Change of inventor or designer information